Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: Biological mechanisms and clinical aspects;Farmaci anti-citochine ed infezioni nei pazienti affetti da artrite reumatoide: Meccanismi biologici ed aspetti clinici

Reumatismo

Volumn 55, Issue 4, 2003, Pages 224-235

  Botsios, Costantino ^a,c   Ostuni, P ^a   Sfriso, P ^a   Furlan, A ^a   Fiocco, U ^a   Sgarabotto, D ^b   Todesco, S ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Cattedra e Divisione di Reumatologia   (Italy)

Author keywords

Adalimumab; Anakinra; Etanercept; Infections; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTISONE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; PENICILLAMINE DERIVATIVE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIGEN BINDING; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTION; INFECTION COMPLICATION; INFECTION RESISTANCE; INFECTION RISK; INFLAMMATION; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; OPPORTUNISTIC INFECTIONS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642434549     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Mitchell WS, Brooks PM, Stevenson RD, Buchanan WW. Septic arthritis in patients with rheumatoid disease: a still underdiagnosed complication. J Rheumatol 1976; 3: 124-33.
2. Rimoin DL, Wennberg JE. Acute septic arthritis complicating chronic rheumatoid arthritis. JAMA 1966; 196: 617-21.
3. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971; 14: 135-7.
4. Goldenberg DL. Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders. Arthritis Rheum 1989; 32: 496-502.
5. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ 1985; 290: 1797-9.
6. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92-9.
7. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H, Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 149-53.
8. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-9.
9. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 87-93.
10. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23.
11. van Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 1988; 31: 667-71.
12. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 37-44.
13. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63.
14. Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224-8.
15. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 188-94.
16. Andersen PA, West SG, Nordstrom DM. Toxicity of chronic therapy with pulse methotrexate in rheumatoid arthritis: potential increased risk of infection [abstract]. Arthritis Rheum 1987; 30 Suppl 4: S60.
17. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
18. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24: 411-21.
19. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95: 14447-52.
20. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97: 9203-8.
21. Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997; 23: 219-37.
22. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
23. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomised controlled trial. Ann Int Med; 1999; 130: 478-86.
24. Lipsky PE, van der Heijde D, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
25. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
26. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 5-45.
27. keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-ct neutralizing agent. N Engl J Med 2001; 345: 98-104.
28. Dinarello CA. Anti-cytokine therapeutics and infectious. Vaccine 2003; 21 (Suppl 2): 24-34.
29. Dinarello C, Moldawer L. The role of cytokines in host defence against infection. In: Dinarello C, Moldawer L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. A primer for Clinicians. 3th ed. Amgen Inc., 2002; 25-52.
30. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 2002; 65 (suppl): 3-8.
31. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature, 1987; 330: 62-4.
32. Berger DP, Naniche D, Crowley MT, Koni PA, Flavell RA, Oldstone MB. Lymphotoxin-beta-deficient mice show defective antiviral immunity. Virology 1999; 260: 36-47.
33. Heremans H, Van Damme J, Dillen C, Dijkmans R, Billiau A. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med 1990; 171: 853-69.
34. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 1998; 9: 1-11.
35. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000; 3: 10-6.
36. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995; 4: 9-95.
37. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-6.
38. Echtenacher B, Hultner L, Mannel DN. Cellular and molecular mechanisms of TNF production in septic peritonitis. J Inflamm 1995; 47: 85-9.
39. Echtenacher B, Weigl K, Lehn N, Mannel DN. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001; 69: 3550-5.
40. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, Norton JA. Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 1992; 112: 188-93.
41. Remick DG, Call DR, Ebong SJ, Newcomb DE, Nybom P, Nemzek JA, et al. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonists decreases sepsis mortality. Crit Care Med 2001; 9: 73-81.
42. van der Poll T, Keogh CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155: 3-8.
43. O'Brien DP, Briles DE, SzaIai AJ, Tu AH, Sanz I, Nahm MH. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 1999; 7: 95-601.
44. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002; 282: 85-90.
45. Rogers HW, Sheehan KC, Brunt LM, Dower SK, Unanue ER, Schreiber RD. Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. Proc Natl Acad Sci USA 1992; 89: 1011-15.
46. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal PB. Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol 1992; 148: 1486-92.
47. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin-1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 1996; 93: 11008-13.
48. Yamamoto T, Sashinami H, Takaya A, Tomoyasu T, Matsui H, Kikuchi Y, et al. Disruption of the genes for ClpXP protease in Salmonella enterica serovar Typhimurium results in persistent infection in mice, and development of persistence requires endogenous gamma interferon and tumor necrosis factor alpha. Infect Immun 2001; 69: 164-74.
49. Vazquez-Torres A, Fantuzzi G, Edwards CK, Dinarello CA, Fang FC. Defective localization of the NADPH phagocyte oxidase to Salmonella containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci USA 2001; 98: 2561-65.
50. Mastroeni P, Arena A, Costa GB, Libero MC, Bonina L, Hormaeche CE. Serum TNF alpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNF-alpha antibodies. Microb Pathog 1991; 11: 3-8.
51. Nauciel C, Espinasse-Maes F. Role of gamma interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60: 450-4.
52. Kincy-Cain T, Clements JD, Bost KL. Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infect Immun 1996; 64: 1437-40.
53. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 2000; 119: 1148-57.
54. Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G, et al. Infection of human macrophages and dentritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 2001; 166: 7033-41.
55. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162: 3504-11.
56. Pfeffer K, Matsuyama T, Kunding TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55Kd tumor necrosis factor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 1993; 73: 457-67.
57. Kaufmann S. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1: 20-30.
58. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-72.
59. Juffermans NP, Florquin S, Camoglio L, Verbon A, Kolk AH, Speelman P, et al. Interleukin-1 signaling is essential for host defence during murine pulmonary tuberculosis. J Infect Dis 2000, 182: 902-8.
60. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6 deficient mutant mice. Infect Immun 1997; 65: 4843-9.
61. Food and Drug Administration, Arthritis Advisory Committee Briefing Document, March 4; 2003. Food and Drug Administration Web site: www.fda.gov.
62. Food and Drug Administration, Arthritis Advisory Committee Briefing Document, August 17; 2001. Food and Drug Administration Web site: www.fda.gov.
63. Manadan AM, Mahan AK, Cote TR, Siegel JN, Sequeira W, Block JA. Tuberculosis and etanercept. Proceedings of American College of Rheumatology Conference; October 2002; abst 356.
64. Gardam M, Keystone E, Menzies R, Manners S, Skamene E, Long R, Vinh D. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
65. Long R, ed. Canadian Tuberculosis Standards, 5th edn. Canadian Lung Association, Health Canada, 2000.
66. Cisneros JR, Murray KM. Corticosteroids in tuberculosis. Ann Pharmacother 1996; 30: 1298-303.
67. Lucas R, Tacchini-Cottier F, Guler R, Vesin D, Jemelin S, Olleros ML, et al. A role for lymphotoxin beta receptor in host defense against Mycobacterium Bovis BCG infection. Eur J Immunol 1999; 29: 4002-10.
68. Cree IA, Nurbhai S, Milne G, Beck JS. Cell death in granulomata: the role of apoptosis. J Clin Pathol 1987; 40: 1314-9.
69. Klingler K, Tchou-Wong KM, Brandli O, Aston C, Kim R, Chi C, et al. Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Infect Immun 1997; 65: 5272-8.
70. Fayyazi A, Eichmeyer B, Soruri A, Schweyer S, Herms J, Schwarz P, et al. Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol 2000; 191: 417-25.
71. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-7.